Your browser is no longer supported. Please, upgrade your browser.
Supernus Pharmaceuticals, Inc.
Index- P/E15.99 EPS (ttm)1.85 Insider Own1.20% Shs Outstand53.01M Perf Week-1.20%
Market Cap1.55B Forward P/E12.21 EPS next Y2.43 Insider Trans0.00% Shs Float51.00M Perf Month10.59%
Income100.20M PEG9.46 EPS next Q0.23 Inst Own- Short Float15.06% Perf Quarter7.08%
Sales571.00M P/S2.71 EPS this Y12.60% Inst Trans0.02% Short Ratio19.74 Perf Half Y-5.51%
Book/sh14.82 P/B2.00 EPS next Y166.16% ROA6.60% Target Price35.00 Perf Year48.00%
Cash/sh7.86 P/C3.77 EPS next 5Y1.69% ROE13.40% 52W Range17.20 - 34.29 Perf YTD17.89%
Dividend- P/FCF13.10 EPS past 5Y53.00% ROI11.70% 52W High-13.50% Beta1.20
Dividend %- Quick Ratio2.00 Sales past 5Y28.70% Gross Margin86.00% 52W Low72.44% ATR0.96
Employees563 Current Ratio2.30 Sales Q/Q11.50% Oper. Margin25.60% RSI (14)58.70 Volatility3.43% 3.24%
OptionableYes Debt/Eq0.47 EPS Q/Q-32.90% Profit Margin17.50% Rel Volume1.07 Prev Close30.68
ShortableYes LT Debt/Eq0.47 EarningsAug 04 AMC Payout0.00% Avg Volume389.08K Price29.66
Recom2.00 SMA205.94% SMA5010.68% SMA2004.12% Volume423,092 Change-3.32%
Apr-13-21Upgrade Jefferies Hold → Buy $25 → $40
Jun-16-20Upgrade Piper Sandler Neutral → Overweight $25 → $31
Jun-15-20Resumed Jefferies Hold $24
Nov-08-19Downgrade Berenberg Buy → Hold
Nov-07-19Downgrade Stifel Buy → Hold $55 → $23
Nov-06-19Downgrade Jefferies Buy → Hold $46 → $23
Nov-12-18Reiterated B. Riley FBR Buy $68 → $65
Jan-18-18Reiterated B. Riley FBR, Inc. Buy $54
Dec-28-17Reiterated B. Riley FBR, Inc. Buy $50 → $54
Dec-04-17Upgrade Janney Neutral → Buy
Nov-08-17Upgrade Stifel Hold → Buy $47
Oct-19-17Initiated FBR & Co. Buy $53
Sep-19-17Downgrade Stifel Buy → Hold $47
Jul-17-17Downgrade Piper Jaffray Overweight → Neutral
Jul-14-17Initiated Janney Neutral
Jun-01-17Upgrade Piper Jaffray Neutral → Overweight
Jul-18-16Downgrade Piper Jaffray Overweight → Neutral
Jul-18-16Downgrade Northland Capital Outperform → Market Perform
Feb-08-16Upgrade Jefferies Hold → Buy
Nov-05-15Reiterated Northland Capital Outperform $26 → $27
Oct-19-21 02:24PM  
Oct-15-21 02:33PM  
Oct-14-21 03:32PM  
Oct-12-21 12:25PM  
Oct-11-21 07:53PM  
Sep-13-21 01:06PM  
Sep-03-21 11:45AM  
Sep-02-21 06:45PM  
Aug-18-21 02:26PM  
Aug-07-21 04:17AM  
Aug-04-21 11:01PM  
Jul-28-21 03:03PM  
Jul-22-21 04:37PM  
Jul-16-21 06:30AM  
Jun-18-21 06:20AM  
Jun-10-21 01:21PM  
Jun-01-21 04:55AM  
May-25-21 08:30AM  
May-24-21 08:30AM  
May-05-21 10:01PM  
May-04-21 08:49PM  
Apr-28-21 12:34PM  
Apr-27-21 05:44PM  
Apr-05-21 08:07PM  
Apr-04-21 06:11AM  
Apr-02-21 04:58PM  
Mar-24-21 06:12AM  
Feb-27-21 06:15AM  
Feb-26-21 10:01AM  
Feb-25-21 04:37PM  
Feb-23-21 09:00AM  
Feb-22-21 08:00AM  
Feb-08-21 09:00AM  
Feb-04-21 04:10PM  
Feb-03-21 06:52AM  
Jan-25-21 02:20PM  
Jan-12-21 12:48PM  
Jan-06-21 05:29PM  
Dec-24-20 10:02AM  
Dec-23-20 02:28PM  
Dec-22-20 06:53PM  
Dec-07-20 10:56AM  
Nov-28-20 11:50PM  
Nov-27-20 11:00AM  
Nov-26-20 12:30AM  
Nov-23-20 10:00PM  
Nov-22-20 01:37AM  
Nov-19-20 03:30PM  
Nov-18-20 10:00PM  
Nov-16-20 11:00PM  
Nov-14-20 03:00PM  
Nov-11-20 09:45PM  
Nov-10-20 08:40AM  
Nov-09-20 06:30PM  
Nov-04-20 01:30PM  
Nov-03-20 05:45PM  
Oct-27-20 05:30PM  
Oct-13-20 01:13PM  
Oct-05-20 04:00PM  
Sep-28-20 10:01AM  
Sep-25-20 07:09AM  
Sep-24-20 07:10AM  
Sep-14-20 08:15AM  
Sep-09-20 04:30PM  
Sep-02-20 04:30PM  
Aug-19-20 12:00PM  
Aug-18-20 07:25PM  
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise APOKYN, a product indicated for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO, a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults. In addition, its product candidates include SPN-812, which has completed Phase III clinical trials that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a novel product candidate in Phase I clinical trials for treatment resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc. to conduct a Phase II clinical program for NV-5138 in treatment-resistant depression. The company was founded in 2005 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SIEBERT JOHN MDirectorAug 11Option Exercise12.9815,000194,70075,953Aug 12 04:32 PM
Martin Tami TillotsonSr. V.P., Regulatory AffairsApr 14Option Exercise12.983,12540,56289,451Apr 14 08:24 PM
Martin Tami TillotsonSr. V.P., Regulatory AffairsApr 14Sale31.983,12599,93886,326Apr 14 08:24 PM
Martin Tami TillotsonSr. V.P., Regulatory AffairsApr 13Option Exercise12.983,12540,56289,451Apr 14 08:24 PM
Martin Tami TillotsonSr. V.P., Regulatory AffairsApr 13Sale29.983,12593,70286,326Apr 14 08:24 PM
Schwabe Stefan K.F.Executive Vice President & CMODec 21Option Exercise12.9846,347601,58449,119Dec 22 05:49 PM
Schwabe Stefan K.F.Executive Vice President & CMODec 21Sale22.1046,3471,024,4632,772Dec 22 05:49 PM
Schwabe Stefan K.F.Executive Vice President & CMODec 14Option Exercise9.3953,653503,91656,425Dec 15 08:20 PM
Schwabe Stefan K.F.Executive Vice President & CMODec 14Sale21.8753,6531,173,2642,772Dec 15 08:20 PM
PATRICK GREGORY SSr. VP Chief Financial OfficerNov 09Option Exercise12.985,00064,90049,463Nov 10 04:19 PM
PATRICK GREGORY SSr. VP Chief Financial OfficerNov 09Sale25.005,000125,00044,463Nov 10 04:19 PM
PATRICK GREGORY SSr. VP, CFONov 05Option Exercise12.985,00064,90049,463Nov 06 05:43 PM
PATRICK GREGORY SSr. VP, CFONov 05Sale23.005,000115,00044,463Nov 06 05:43 PM